EGFR-IN-107 

EGFR-IN-107 (compound 3r) is an orally active EGFR inhibitor with IC₅₀ values of 0.4333 μM for EGFR^WT and 0.0438 μM for EGFR^L858R/T790M. EGFR-IN-107 has anti-proliferative activity and can inhibit the proliferation of H1975 cells and induce their apoptosis. EGFR-IN-107 can be used in cancer research^[1].

EGFR-IN-107 (compound 3r) has an IC₅₀ value of 5 nM for EGFR kinase^[1].
EGFR-IN-107 has an IC₅₀ value of 1.9 μM against the Osimertinib (HY-15772 ) -resistant H1975 cell line (H1975OR)^[1].
EGFR-IN-107 (1 μM, 24 h) induces apoptosis and inhibits cell migration in H1975 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

EGFR-IN-107 (compound 3r) (5, 10, 20 mg/kg; Oral gavage (p.o.); 21 days) has strong antitumor activity in H1975 xenografted mouse models and can significantly inhibit the proliferation of H1975 xenografted mouse models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

593.69

C₃₄H₃₆FN₇O₂

C=CC(NC1=C(C=C(C(NC2=NC(C3=C(N(C4=C3C=CC=C4)C)C5=CC=CC(F)=C5)=CC=N2)=C1)OC)N(CCN(C)C)C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Feng R, et al. Late-stage modification of complex drug: Base-controlled Pd-catalyzed regioselective synthesis and bioactivity of arylated osimertinibs. Sci Adv. 2024 Mar 8;10(10):eadl0026.  [Content Brief]